Cargando…

The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review

With the introduction of targeted therapies and immunotherapy, molecular diagnostics gained a more profound role in the management of non-small cell lung cancer (NSCLC). This study aimed to systematically search for studies reporting on the use of liquid biopsies (LB), the correlation between LBs an...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Delft, Frederik, Koffijberg, Hendrik, Retèl, Valesca, van den Heuvel, Michel, IJzerman, Maarten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280996/ https://www.ncbi.nlm.nih.gov/pubmed/32365836 http://dx.doi.org/10.3390/cancers12051120

Ejemplares similares

Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy
por: van Delft, Frederik, et al.
Publicado: (2021)

Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer
por: van Delft, Frederik A., et al.
Publicado: (2022)

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer
por: van de Ven, Michiel, et al.
Publicado: (2022)

Whole genome sequencing in oncology: using scenario drafting to explore future developments
por: van de Ven, Michiel, et al.
Publicado: (2021)

Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility
por: Berghuis, A. M. Sofie, et al.
Publicado: (2017)

The value of time-dependent risk predictions in a screening context - a comprehensive simulation analysis validated on German cancer registry data
por: Voelkel, Vinzenz, et al.
Publicado: (2022)

Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models
por: Degeling, Koen, et al.
Publicado: (2017)

Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
por: IJzerman, Maarten J., et al.
Publicado: (2017)

Point‐of‐care testing in primary care: A systematic review on implementation aspects addressed in test evaluations
por: Lingervelder, Deon, et al.
Publicado: (2019)

Health Economic Evidence of Point-of-Care Testing: A Systematic Review
por: Lingervelder, Deon, et al.
Publicado: (2021)

Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process
por: Degeling, Koen, et al.
Publicado: (2020)

Tailoring the Implementation of New Biomarkers Based on Their Added Predictive Value in Subgroups of Individuals
por: van Giessen, A., et al.
Publicado: (2015)

Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer
por: Degeling, Koen, et al.
Publicado: (2018)

Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation
por: Behr, Carina M., et al.
Publicado: (2022)

External validation of 87 clinical prediction models supporting clinical decisions for breast cancer patients
por: Hueting, Tom A., et al.
Publicado: (2023)

Toward Alignment in the Reporting of Economic Evaluations of Diagnostic Tests and Biomarkers: The AGREEDT Checklist
por: Kip, Michelle M.A., et al.
Publicado: (2018)

The societal impact of implementing an at-home blood sampling device for chronic care patients: patient preferences and cost impact
por: Lingervelder, Deon, et al.
Publicado: (2022)

Facilitating validation of prediction models: a comparison of manual and semi-automated validation using registry-based data of breast cancer patients in the Netherlands
por: van Steenbeek, Cornelia D., et al.
Publicado: (2019)

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022)

The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care
por: Kip, Michelle M. A., et al.
Publicado: (2017)

Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations
por: Behr, Carina M., et al.
Publicado: (2023)

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Evidence on the cost of breast cancer drugs is required for rational decision making
por: Berghuis, Anne Margreet Sofie, et al.
Publicado: (2018)

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019)

Early budget impact analysis on magnetic seed localization for non-palpable breast cancer surgery
por: Lindenberg, Melanie, et al.
Publicado: (2020)

From accuracy to patient outcome and cost-effectiveness evaluations of diagnostic tests and biomarkers: an exemplary modelling study
por: Koffijberg, Hendrik, et al.
Publicado: (2013)

Subtype prediction in pediatric acute myeloid leukemia: classification using differential network rank conservation revisited
por: Obulkasim, Askar, et al.
Publicado: (2015)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

The predictive validity of three self-report screening instruments for identifying frail older people in the community
por: Daniels, Ramon, et al.
Publicado: (2012)

Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value
por: Walker, Michael J., et al.
Publicado: (2015)

Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis
por: Kip, Michelle M. A., et al.
Publicado: (2019)

The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor
por: Nerad, Elias, et al.
Publicado: (2019)

A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
por: Oberije, Cary, et al.
Publicado: (2015)

Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments
por: van Harten, Wim, et al.
Publicado: (2017)

Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value
por: Gillett, Piers, et al.
Publicado: (2023)

Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study
por: Blanken, Maarten O., et al.
Publicado: (2013)

There is no such thing as a validated prediction model
por: Van Calster, Ben, et al.
Publicado: (2023)

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2022)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product
por: Lindenberg, Melanie A., et al.
Publicado: (2018)

PREDICT, Prediction of Delirium in ICU Patients: development and validation of a prediction model
por: Boogaard, M Van den, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2a5gvpamtmsfcvcrm9bb928de9